Spots Global Cancer Trial Database for stage iv colon cancer ajcc v8

Every month we try and update this database with for stage iv colon cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	NCT03992456	Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Panitumumab Quality-of-Life... Questionnaire A... Regorafenib Trifluridine an...	18 Years -	Academic and Community Cancer Research United
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial	NCT03765736	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Genetic Testing	18 Years -	Academic and Community Cancer Research United
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases	NCT04752267	Anatomic Stage ... Clinical Stage ... Glioma Malignant Brain... Metastatic Brea... Metastatic Colo... Metastatic Kidn... Metastatic Lung... Metastatic Mali... Metastatic Mela... Pathologic Stag... Prognostic Stag... Stage IV Colon ... Stage IV Lung C... Stage IV Renal ... Stage IVA Colon... Stage IVA Lung ... Stage IVB Colon... Stage IVB Lung ... Stage IVC Colon...	Computed Tomogr... 18F-FMAU Multiparametric... Positron Emissi...	18 Years -	University of Southern California
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery	NCT05296681	Metastatic Colo... Stage IV Colon ... Stage IVA Colon... Stage IVB Colon... Stage IVC Colon...	NBT-NM108	18 Years -	Rutgers, The State University of New Jersey
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events	NCT05038254	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Colo... Metastatic Esop... Metastatic Gast... Metastatic Live... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Panc... Metastatic Rect... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage IV Colon ... Stage IV Hepato... Stage IV Pancre... Stage IV Rectal... Stage IV Small ... Stage IVA Colon... Stage IVA Hepat... Stage IVA Recta... Stage IVB Colon... Stage IVB Hepat... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta...	Best Practice Patient Monitor... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	NCT05308446	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	National Cancer Institute (NCI)
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery	NCT05296681	Metastatic Colo... Stage IV Colon ... Stage IVA Colon... Stage IVB Colon... Stage IVC Colon...	NBT-NM108	18 Years -	Rutgers, The State University of New Jersey
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases	NCT04752267	Anatomic Stage ... Clinical Stage ... Glioma Malignant Brain... Metastatic Brea... Metastatic Colo... Metastatic Kidn... Metastatic Lung... Metastatic Mali... Metastatic Mela... Pathologic Stag... Prognostic Stag... Stage IV Colon ... Stage IV Lung C... Stage IV Renal ... Stage IVA Colon... Stage IVA Lung ... Stage IVB Colon... Stage IVB Lung ... Stage IVC Colon...	Computed Tomogr... 18F-FMAU Multiparametric... Positron Emissi...	18 Years -	University of Southern California
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial	NCT03765736	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Genetic Testing	18 Years -	Academic and Community Cancer Research United
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study	NCT04109924	Advanced Colore... Metastatic Colo... Metastatic Rect... Recurrent Colon... Recurrent Color... Recurrent Recta... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IV Colon ... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Irinotecan Bevacizumab Trifluridine an...	18 Years -	Roswell Park Cancer Institute
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	NCT05308446	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	National Cancer Institute (NCI)
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery	NCT05296681	Metastatic Colo... Stage IV Colon ... Stage IVA Colon... Stage IVB Colon... Stage IVC Colon...	NBT-NM108	18 Years -	Rutgers, The State University of New Jersey
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	NCT05356897	Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal...	Trastuzumab Trifluridine an... Tucatinib	18 Years -	Academic and Community Cancer Research United
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer	NCT03592641	Colorectal Carc... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Savolitinib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: